Utility of prechemotherapy evaluation of left ventricular function for patients with lymphoma.

[1]  R. Advani,et al.  Hodgkin lymphoma. , 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

[2]  M Ladetto,et al.  Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  R. Go,et al.  Utility of routine left ventricular ejection fraction measurement before anthracycline-based chemotherapy in patients with diffuse large B-cell lymphoma. , 2012, Journal of oncology practice.

[4]  W. Johnson,et al.  Pretreatment and routine echocardiogram monitoring during chemotherapy for anthracycline‐induced cardiotoxicity rarely identifies significant cardiac dysfunction or alters treatment decisions , 2012, Cancer.

[5]  D. Rayson,et al.  Routine cardiac evaluation in patients with early-stage breast cancer before adjuvant chemotherapy. , 2012, Clinical breast cancer.

[6]  B. Koczwara,et al.  Utility of prechemotherapy echocardiographical assessment of cardiac abnormalities , 2011, Supportive Care in Cancer.

[7]  Taurino Avelar,et al.  Clinical impact of the baseline echocardiogram in children with high‐risk acute lymphoblastic leukemia , 2011, Pediatric blood & cancer.

[8]  D. V. Von Hoff,et al.  A historical perspective of anthracycline cardiotoxicity. , 2011, Heart failure clinics.

[9]  R. Greil,et al.  Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. , 2010, The New England journal of medicine.

[10]  Q. Bashir,et al.  Cardiotoxicity of cancer therapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  E. Antman,et al.  ACC/AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Cardiac Radionucl , 2003, Journal of the American College of Cardiology.

[12]  E. Antman,et al.  ACC/AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Cardiac Radionucl , 2003, Journal of the American College of Cardiology.

[13]  D. Faxon,et al.  ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echoca , 2003, Journal of the American College of Cardiology.

[14]  S. Swain,et al.  Congestive heart failure in patients treated with doxorubicin , 2003, Cancer.

[15]  B. Jensen,et al.  Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  J. T. Bricker,et al.  Evaluation of Left Ventricular Function in Asymptomatic Children About to Undergo Anthracycline-Based Chemotherapy for Acute Leukemia: An Outcome Study , 2001, Journal of pediatric hematology/oncology.

[17]  S. Edge,et al.  Is MUGA Scan Necessary in Patients With Low‐Risk Breast Cancer Before Doxorubicin‐Based Adjuvant Therapy? , 2001, American journal of clinical oncology.

[18]  P. Singal,et al.  Doxorubicin-induced cardiomyopathy. , 1998, The New England journal of medicine.

[19]  R. Dreicer,et al.  The role of radionuclide angiocardiography in the treatment of patients receiving doxorubicin-based chemotherapy: a reassessment. , 1997, American journal of clinical oncology.

[20]  S. Proctor,et al.  Non-Hodgkin's Lymphomas , 1994, British Journal of Cancer.

[21]  R. Schwartz,et al.  Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Childrens Cancer Study Group. , 1992, Pediatrics.

[22]  R. Bonow,et al.  Prospective evaluation of doxorubicin cardiotoxicity by rest and exercise radionuclide angiography. , 1986, The American journal of cardiology.

[23]  D. V. Von Hoff,et al.  Risk factors for doxorubicin-induced congestive heart failure. , 1979, Annals of internal medicine.

[24]  R. Arceci.  Anthracycline-Related Cardiomyopathy After Childhood Cancer: Role of Polymorphisms in Carbonyl Reductase Genes—A Report From the Children's Oncology Group , 2012 .

[25]  M. Dreyling,et al.  Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  M. Adamcová,et al.  Anthracycline-induced cardiotoxicity. , 2000, Acta medica.